The pharmaceutical landscape of the 21st century has been fundamentally altered by the rise of glucagon-like peptide-1 (GLP-1) receptor agonists.…
Read More
New Study Reveals Oral Semaglutide Outperforms Orforglipron in Weight Loss and Tolerability
Findings presented at the 33rd European Congress on Obesity in Istanbul, Turkey, on May 15th, have provided a crucial comparative…
Read More
Foundayo Demonstrates Efficacy in Sustaining Weight Loss Post-Injectable Incretin Therapy, Presenting a Novel Oral Option
On May 13, 2024, at the 33rd European Congress on Obesity (ECO) held in Istanbul, Türkiye, groundbreaking Phase 3b trial…
Read More
Salk Institute Researchers Identify BCL6 Protein as Key to Preventing Muscle Loss During GLP-1 Weight Management and Aging
The rapid rise of glucagon-like peptide-1 (GLP-1) receptor agonists has fundamentally transformed the landscape of metabolic medicine, offering unprecedented efficacy…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Beyond the Weight Room: The Evolving Science and Therapeutic Potential of Creatine Supplementation
The scientific understanding of creatine has undergone a significant transformation, moving from its traditional reputation as a niche bodybuilding aid…
Read More
Eli Lilly Soars Past Expectations on Unabated Weight-Loss Drug Demand, Raises Full-Year Forecast
Eli Lilly and Company has once again demonstrated its formidable market power, reporting first-quarter 2026 sales that significantly surpassed analyst…
Read More
Mistral AI Unveils Voxtral TTS: A New Era of Open-Weight, Real-Time Text-to-Speech
Mistral AI, a prominent European artificial intelligence firm, has introduced Voxtral TTS, a groundbreaking open-weight text-to-speech (TTS) model designed to…
Read More
Salk Institute Researchers Identify BCL6 Protein as Key to Preventing Muscle Loss During GLP-1 Weight Management and Aging
The pharmaceutical landscape of the 21st century has been fundamentally altered by the advent of glucagon-like peptide-1 (GLP-1) receptor agonists.…
Read More
Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read MoreYOU MAY HAVE MISSED
